Subsequently, the efficacy of CC-115, a dual TORK/DNA-PK inhibitor that simultaneously targets NHEJ and BCR signaling, was evaluated in individuals with ATM-defective relapsed/refractory CLL or small lymphocytic lymphoma (SLL), eliciting a partial response in 3 of 8 patients [93,149]. The gene discussed is PRKDC; the disease is B-cell chronic lymphocytic leukemia.